Vanguard Russell 1000 Growth vs. Invesco SmallCap 600 Revenue: Which Is Better for a Diversified Portfolio?

Invesco's RZG returned 22.3% over the trailing 12 months versus 6.9% for Vanguard's VONG, but VONG generated stronger five-year growth, turning $1,000 into $1,742 versus $1,260 for RZG. VONG offers low-cost large-cap growth exposure at a 0.06% expense ratio and is concentrated in technology (68%), led by Nvidia, Alphabet and Apple; RZG charges 0.35% and targets revenue-weighted small caps, with healthcare, industrials and financials comprising its largest sector exposures. The comparison frames RZG as a potentially higher-growth but more volatile diversification option for investors already heavily exposed to mega-cap technology.

Analysis

This is primarily an allocation/positioning signal rather than a company-specific catalyst. VONG is effectively a high-duration AI and internet-platform basket with substantial single-name overlap versus QQQ/SPY; incremental flows into it are unlikely to change NVDA, GOOG, or AAPL pricing, but its concentration makes it vulnerable to a simultaneous de-rating if AI capex returns disappoint or real yields rise. RZG's revenue-weighting reduces pure market-cap momentum exposure, yet its small asset base and thinner underlying liquidity make it an imperfect institutional vehicle for expressing a small-cap rotation.

The more actionable second-order read is that a durable broadening trade should favor profitable domestic small-cap industrial, specialty-finance, and semiconductor-equipment names over pre-revenue biotech risk. ACMR would benefit from a semiconductor-capex recovery but retains China/export-control and customer-concentration risk; DAVE is more sensitive to credit losses and consumer liquidity than to a generic small-cap beta move; PTGX remains driven by trial/regulatory outcomes, not factor rotation. Thus, RZG's recent relative strength should not be extrapolated as evidence of a uniform small-cap earnings inflection.

Over the next 1-3 months, relative performance hinges on the path of real rates, Fed easing expectations, and whether earnings revisions broaden beyond mega-cap technology. A falling-yield/soft-landing regime can extend both growth and small-cap multiples, but a growth scare would likely expose small-cap balance-sheet fragility first; over 6-18 months, broadening requires improving small-cap free-cash-flow and refinancing conditions. Falsify a small-cap-over-mega-cap thesis if Russell 2000 earnings revisions remain negative while 10-year real yields move higher, or if AI leaders again deliver upward revenue and capex revisions.

Key Decisions for Investors

• No standalone trade in RZG or VONG: the article adds no incremental fundamental catalyst, and RZG's modest AUM can create execution/tracking risk for institutional sizing.
• For an existing mega-cap growth overweight, use a 1-3 month hedged rotation expression: long IWM or IJR / short QQQ, sized beta-neutral. Target 5-8% relative upside if real yields decline and earnings breadth improves; exit if 10-year real yields rise materially or small-cap revisions deteriorate.
• Keep NVDA and GOOG exposure separate from a VONG allocation decision. Add only on independently verifiable upward revenue/FCF revisions; reduce if hyperscaler capex guidance stops translating into AI revenue growth, as ETF flow narratives will not protect concentrated valuations.
• Treat ACMR, DAVE, and PTGX as idiosyncratic watch items rather than small-cap proxies: require evidence of order growth for ACMR, stable delinquency/net-charge-off trends for DAVE, and clinical/regulatory milestones for PTGX before initiating positions.